Anti-β_2-glycoprotein Ⅰ antibodies in patients with systemic lupus erythematosus

NING Xin-rong,ZHAO Yi,LIU Zong-ping,LI Zhan-guo
2006-01-01
Abstract:Objective To investigate the prevalence and significance of anti-β2-glycoprotein Ⅰ (anti-β2-GPⅠ) in patients with systemic lupus erythematosus (SLE). Methods Anti-β2-GPⅠ level was determined in 112 SLE patients, 40 patients with rheumatoid arthritis (RA), 30 patients with Sj?gren′s syndrome (SS) and 40 healthy individuals by enzyme-linked immunosorbent assay (ELISA). The laboratory and clinical features (thrombosis, fetal loss, etc) were analyzed retrospectively from the clinical database. Results Sensitivities of anti-β2-GPⅠ were 21.4%, 15.0%, 6.7% in SLE, RA and SS, respectively. The specificity of anti-β2-GPⅠ was 88.6% in SLE. Correlations between thrombosis and titers of ACL-IgG/IgM and anti-β2-GPⅠ were statistically significant. No association was found between anti-β2-GPⅠ and other clinical and laboratory features. Conclusion The results indicate that anti-β2-glycoprotein Ⅰ antibodies are common and may play a role in SLE with thrombosis. Combination of ACL and anti-β2-GPⅠ can facilitate the diagnosis of SLE with thrombosis.
What problem does this paper attempt to address?